A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Short Title: PARAISO

Enrollment Status: Recruiting

NCT #: NCT07174310

Specialty Area: Neurology

Condition Studied: Parkinson's Disease

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 50-85 years of age
Diagnosed with idiopathic Parkinson's Disease (PD) based on Movement Disorder Society (MDS) criteria
Has received monotherapy treatment
Hoehn and Yahr (H&Y) Stage 1 or 2 off medication
An MDS-UPDRS Part IV score of 0
No diagnosis of a significant neurologic disease other than PD
No chronic uncontrolled hypertension

What's Involved

Participation in the study will include:

Participation in the study will include:

Intravenous (IV) infusion of the study medication or placebo

Principal Investigator

Danny Truong, DO

General Neurology

A Member of

(775) 982–5000

Renown Institute for Neurosciences

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT07174310

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews